Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

por Zahir, Hamim, Greenberg, Jonathan, Shuster, Dale, Hsu, Ching, Watanabe, Kengo, LaCreta, Frank
Publicado 2022

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors

por Yin, Ophelia, Wagner, Andrew J., Kang, Jia, Knebel, William, Zahir, Hamim, van de Sande, Michiel, Tap, William D., Gelderblom, Hans, Healey, John H., Shuster, Dale, Stacchiotti, Silvia
Publicado 2020

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor

por Yin, Ophelia, Zahir, Hamim, French, Jonathan, Polhamus, Daniel, Wang, Xiaoning, van de Sande, Michiel, Tap, William D., Gelderblom, Hans, Wagner, Andrew J., Healey, John H., Greenberg, Jonathan, Shuster, Dale, Stacchiotti, Silvia
Publicado 2021

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

por Lewis, James H., Gelderblom, Hans, van de Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia‐Chi, Baba, Hideo A., Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian
Publicado 2020

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial

por Van De Sande, Michiel, Tap, William D, Gelhorn, Heather L, Ye, Xin, Speck, Rebecca M, Palmerini, Emanuela, Stacchiotti, Silvia, Desai, Jayesh, Wagner, Andrew J, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Wang, Qiang, Shuster, Dale, Gelderblom, Hans, Healey, John H
Publicado 2021

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

por Personeni, Nicola, Giordano, Laura, Abbadessa, Giovanni, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Laethem, Jean-Luc Van, Vlierberghe, Hans Van, Trojan, Jörg, De Toni, Enrico N., Gasbarrini, Antonio, Lencioni, Monica, Lamar, Maria E., Wang, Yunxia, Shuster, Dale, Schwartz, Brian, Santoro, Armando, Rimassa, Lorenza
Publicado 2017

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

por Rimassa, Lorenza, Abbadessa, Giovanni, Personeni, Nicola, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Salvagni, Stefania, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Trojan, Jörg, De Toni, Enrico N., Weiss, Alan, Miles, Steven, Gasbarrini, Antonio, Lencioni, Monica, Lamar, Maria E., Wang, Yunxia, Shuster, Dale, Schwartz, Brian E., Santoro, Armando
Publicado 2016

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors

por Gelderblom, Hans, Wagner, Andrew J., Tap, William D., Palmerini, Emanuela, Wainberg, Zev A., Desai, Jayesh, Healey, John H., van de Sande, Michiel A. J., Bernthal, Nicholas M., Staals, Eric L., Peterfy, Charles G., Frezza, Anna Maria, Hsu, Henry H., Wang, Qiang, Shuster, Dale E., Stacchiotti, Silvia
Publicado 2020